Autolus Therapeutics PLC (AUTL) saw its stock soar 9.7% in pre-market trading on Monday, following positive analyst coverage and anticipation of FDA approval for one of its drug candidates.
Goldman Sachs upgraded Autolus Therapeutics to a "Buy" rating from "Neutral" and raised its price target to $7.60, citing the potential approval of the company's lead drug candidate Aucatzyl. Analyst Rajan Sharma noted that FDA approval of Aucatzyl would de-risk Autolus' platform and could lead to significant upside for the stock.
Additionally, analysts polled by Capital IQ have an average "Buy" rating on Autolus Therapeutics, with price targets ranging from $7 to $13, indicating further upside potential if the company's pipeline progresses favorably.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.